Formulation and characterization of solid lipid nanoparticles of rifampicin;katı solid rifampisinin nano-parçacıklarının formülasyon ve karakterizasyonu

Erciyes Tip Dergisi

Volumn 35, Issue 1, 2013, Pages 1-5

  Sivadasan, Durgaramani ^a   Madavan, Bindu ^a   Penmatsa, Shalini Devi ^a   Bathini, Sree Tejaswi ^a  

^a PSG COLLEGE OF PHARMACY   (India)

Author keywords

Nanoparticles; Rifampicin; Stearic acid; Tuberculosis

Indexed keywords

POLYLACTIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; TUBERCULOSIS;

EID: 84877145509     PISSN: 1300199X     EISSN: None     Source Type: Journal    
DOI: 10.5152/etd.2013.01     Document Type: Article

References (11)

1. Eliana B. Souto, Rainer H. Müller, Lipid nanoparticles (SLN and NLC) for drug delivery, In: Domb AJ, Tabata Y, Ravi Kumar MNV, Farber S, Editors. Nanoparticles for Pharmaceutical Applications. Los Angeles, California: American Scientifc Publishers; 2007.p.103-122.
2. Vyas S P, Khar R.K. Targeted and Controlled Drug Delivery: Novel Carrier Systems. 1st ed. New Delphi: CBS Publishers; 2002.
3. Tabatt K, Kneuer C, Sameti M, Olbrich C, Müller RH, Lehr CM, et al. Trans-fection with different colloidal systems: comparison of solid lipid nanopar-ticles and liposomes. J Control Release 2004; 97(2): 321-332.
4. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-196
5. Quenelle DC, Winchester GA, Staas JK, Barrow EL, Barrow W W. Treatment of tuberculosis using a combination of sustained-release rifam-pin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother 2001; 45(6): 1637-1644.
6. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005; 55(4): 430-435.
7. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005; 107(2): 215-228.
8. Vijaya Raghavan C. Experimental Biopharmaceutics and Pharmacoki-netics. 1st ed. India: New Century. 2006.
9. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004; 95(3): 627-638.
10. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antituber-cular chemotherapy. Tuberculosis (Edinb) 2005; 85(5-6): 415-420.
11. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002; 82(1): 105-114.